Seasonal variation in endogenous serum melatonin profiles in goats: a difference between spring and fall?

The pineal hormone melatonin serves as a signal of day length in the regulation of annual rhythms of physiological functions and behavior. The duration of high melatonin levels in body fluids is proportional to the duration of the dark period of the day. Due to the direct suppression of melatonin by light, the overt melatonin rhythm may differ from the endogenous rhythm driven by the hypothalamic circadian clock. The aim of this study was to find out possible differences between the overt and endogenous melatonin rhythms in goats during the course of a year. Seven Finnish landrace goats (nonlactating females) were kept under artificial lighting that approximately simulated the annual changes of day length at 60 degrees N. Blood samples for melatonin measurements by radioimmunoassay were collected at 2-h intervals during six seasons: winter (light:dark 6:18 h), early spring (10:14), late spring (14:10), summer (18:6), early fall (14:10), and late fall (10:14). Melatonin profiles were determined for 2 consecutive days, first in light-dark (LD) conditions and then in continuous darkness (DD). In LD conditions, the profiles matched the dark period with one exception: In winter, the mean peak duration was significantly shorter than the scotoperiod. In DD conditions, two types of endogenous melatonin patterns were found: a "winter pattern" (peak duration 13-15 h) in winter, early spring, early fall, and late fall, and a "summer pattern" (duration about 11 h) in late spring and summer. Thus, in equal habitual LD conditions in late spring and early fall (LD 14:10), the endogenous melatonin rhythms were not quite similar: The pattern in late spring resembled that in summer, and the pattern in early fall that in winter. These results suggest that, in addition to the light-adjusted overt melatonin rhythm, the endogenous rhythm of melatonin secretion varies during the course of a year.

Bright light exposure of a large skin area does not affect melatonin or bilirubin levels in humans.

BACKGROUND: Light treatment through the eyes is effective in alleviating the symptoms of some psychiatric disorders. A recent report suggested that skin light exposure can affect human circadian rhythms. Bilirubin can serve as a hypothetical blood-borne mediator of skin illumination into the brain. We studied whether bright light directed to a large body area could suppress the pineal melatonin secretion or decrease serum total bilirubin in conditions that could be used for therapeutic purposes. METHODS: Seven healthy volunteers participated in two consecutive overnight sessions that were identical except for a light exposure on the chest and abdomen in the second night from 12:00 AM to 6:00 AM (10,000-lux, 32 W/m(2) cool white for six subjects and 3000-lux, 15 W/m(2) blue light for one subject). Hourly blood samples were collected from 7:00 PM to 7:00 AM for melatonin radioimmunoassays. Bilirubin was measured by a modified diazo method in blood samples taken at 12:00 AM and 6:00 AM and in urine samples collected from 7:00 PM to 11:00 PM and from 11:00 PM to 7:00 AM. RESULTS: The skin light exposure did not cause any significant changes in serum melatonin or bilirubin levels. The excretion of bilirubin in urine was also the same in both sessions. CONCLUSIONS: Significant melatonin suppression by extraocular light does not occur in humans. Robust concentration changes of serum total bilirubin do not have a role in mediating light information from the skin to the central nervous system.

No evidence for extraocular light induced phase shifting of human melatonin, cortisol and thyrotropin rhythms.

The view that light affects the mammalian circadian clock only through the eyes was recently challenged by a study in which the phases of human circadian rhythms were shifted by extraocular light exposure. This finding has not been confirmed, however. We studied the effects of light exposure (3 h, broad spectrum fluorescent white light, 13000 lux) on abdomen and chest on the circadian rhythms of serum melatonin, cortisol and thyrotropin in six subjects. The protocol consisted of two 3-day sessions in a dimly lit (< 10 lux) experimental unit. In both sessions hourly serum samples were collected for hormone analysis on days 1 and 3. The skin light exposure was delivered on day 2 from 22.00 to 01.00h in one of the two sessions in a randomized order. In both sessions all three rhythms tended to delay, presumably due to the endogenous circadian cycle length being slightly longer than 24 h. However, the phase shifts did not differ significantly between the sessions. Thus, the present study does not support the existence of extraocular photic regulation of the circadian rhythms in humans.

Evidence for central alpha(2)-adrenergic modulation of rat pineal melatonin synthesis.

This study was performed to distinguish central and peripheral alpha(2)-adrenoceptors in the inhibition of rat pineal melatonin synthesis. The rats received lipo- or hydrophilic alpha(2)-adrenoceptor ligand injections at middark; after 1 or 2 h the pineal melatonin contents were measured. The lipophilic agonist medetomidine (100 microg/kg s.c.) suppressed the melatonin contents significantly, while the hydrophilic agonists ST-91 and p-aminoclonidine (10 or 100 microg/kg i.v.) did not. The suppression by medetomidine was counteracted by the lipophilic antagonist yohimbine (0.3-3.0 mg/kg i.p.) but not by the hydrophilic antagonist L-659,066 (1-10 mg/kg i.v.). In conclusion, the suppression of nocturnal melatonin synthesis by alpha(2)-adrenoceptor agonists is mainly of central origin.

Melatonin release from rat pineals in vitro is stimulated by both the alpha(2)-adrenoceptor agonist medetomidine and the antagonist atipamezole.

This study was done to clarify the role of alpha(2)-adrenoceptors in the regulation of pineal melatonin synthesis. Rat pineal glands were incubated in oxygenated Krebs-Ringer solution in perifusion chambers, and perifused for 30 min with alpha(2)-adrenoceptor ligands. The melatonin concentrations were measured from the perifusate by radioimmunoassay. Both medetomidine and atipamezole (>/=10(-5) M) increased melatonin release. Yohimbine blocked the increase caused by medetomidine but not by atipamezole. The effects of medetomidine and atipamezole were also additive: the maximum response to atipamezole could be significantly increased by medetomidine. These results suggest that the two drugs stimulate the melatonin synthesis through different mechanisms: medetomidine through alpha(2)-adrenoceptors and atipamezole possibly through nonadrenergic mechanisms. The results differ from previous in vivo experiments suggesting that alpha(2)-adrenoceptor ligands affect melatonin synthesis both centrally and locally in the pineal gland. The local effects are most likely masked under the central regulatory systems in vivo.

Suppression of melatonin by 2000-lux light in humans with closed eyelids.

BACKGROUND: In order to clarify the role of light in regulating body functions in sleeping humans, we studied whether the light-sensitive pineal hormone melatonin can be suppressed by facial light exposure in subjects with closed eyelids. METHODS: Eight healthy volunteers participated in 3 nightly sessions: a dim-light control session (< 10 lux) and two light-exposure sessions (2000 lux, 60 min between 2400 and 0200 h). One light exposure occurred with eyes open and the other with eyes closed. Saliva samples were collected at least every hour from 1900 to 0300 h. Melatonin concentrations were measured by radioimmunoassay. RESULTS: Salivary melatonin concentrations decreased only in 2 of the 8 volunteers during light-exposure sessions with eyes closed. On average, light exposure did not decrease the salivary melatonin concentration. CONCLUSIONS: Because indoor illuminance is usually much lower than 2000 lux, light is probably ineffective in regulating the neuroendocrine hypothalamic functions in people during their sleep. Nevertheless, the possibility remains that higher illuminances, often used for therapeutic purposes, can inhibit the secretion of melatonin even in sleeping patients.

Evidence against alpha2-adrenoceptor involvement in the regulation of rat melatonin synthesis by ambient lighting.

This study was carried out to clarify the role of alpha2-adrenoceptors in the regulation of pineal melatonin synthesis. Medetomidine, a selective alpha2-adrenoceptor agonist, was previously found to be a potent suppressor of nocturnal melatonin levels in rats. Medetomidine and alpha2-adrenoceptor antagonists atipamezole and yohimbine were injected into rats in different conditions, and their pineal melatonin contents were measured by radioimmunoassay. Experiment 1: Blocking the alpha2-adrenoceptors and possible non-adrenergic binding sites with atipamezole did not counteract the light-induced suppression of nocturnal melatonin. These receptors are, thus, not essential for the suppression of melatonin by light. Experiment 2: Blocking the alpha2-adrenoceptors with atipamezole or yohimbine did not sensitize the pineal melatonin synthesis to daytime darkness in the light/dark-entrained rats. The binding sites are not involved in keeping the daytime melatonin levels low, even in darkness. Experiment 3: The rats were sensitized to daytime darkness by keeping them for seven days in constant light. The dark-elicited melatonin rise was suppressed by a lower dose of medetomidine than the normal nocturnal rise in light/dark-entrained rats, while atipamezole had no effect. The results showed that alpha2-adrenoceptor insufficiency is not involved in the constant light-induced pineal supersensitivity. In summary, the experiments indicated that the physiological regulation of melatonin synthesis by ambient lighting in rats does not depend on alpha2-adrenergic mechanisms.

Supersensitivity with reduced capacity for pineal melatonin synthesis in constant light-treated rats.

Melatonin is synthetized from serotonin in two steps driven by the enzymes N-acetyltransferase and hydroxyindole-O-methyltransferase. Constant light treatment reduces rat pineal hydroxyindole-O-methyltransferase activity while the activation of N-acetyltransferase becomes supersensitive to adrenergic stimulation. We studied the effect of this discrepancy on the production of melatonin. Male rats were kept under 12/ 12-h light/dark (LD) conditions or for 7 days under constant light (LL). They received subcutaneous injections of isoproterenol or methoxamine in the middle of the light period (LD-rats) or the estimated rest phase (LL-rats). A low dose of isoproterenol (0.1 mg/kg) increased pineal melatonin only marginally in LD-rats, while a maximum effect was found in LL-rats. A medium dose (0.2mg/kg) produced similar levels in both groups. A high dose (0.4 mg/kg) elevated pineal melatonin contents significantly more in normal than light-treated rats. Methoxamine (0.8 mg/kg) had no effects alone nor combined with isoproterenol. The results suggest supersensitivity with reduced capacity for melatonin formation in constant light-treated rats.

Bright light suppresses melatonin in blind patients with neuronal ceroid-lipofuscinoses.

We studied whether light information can reach the pineal glands of clinically blind patients with neuronal ceroid-lipofuscinoses. The suppression of melatonin by light was used as an indicator. Seven patients and seven control subjects were exposed to 3,000-lux light for 60 minutes at the rising phase of the melatonin synthesis. Most patients were not cooperative, and their eyelids were opened by a researcher every 2 minutes for 2 seconds. The control subjects opened and closed their eyes similarly by themselves. Light suppressed melatonin in three of seven control subjects and in all patients. The average postlight levels were 80% (control subjects) and 51% (patients) of the corresponding levels during the dim-light session. Despite degenerated retinas of the blind patients, light can penetrate their visual system to the hypothalamic and pineal levels and regulate neuroendocrine function.

Alpha2-adrenoceptor agonist medetomidine affects the melatonin rhythm in rats.

We investigated whether alpha2-adrenergic mechanisms participate in the regulation of the daily melatonin rhythm. Female Wistar rats, living under 12:12 h light-dark conditions, received a subcutaneous injection of saline or medetomidine (alpha2-adrenoceptor agonist; 100 microg/kg) 1 h after lights off. Thereafter they were kept in continuous darkness. Pineal glands were collected for melatonin measurements at 2-h intervals during the first and second subjective nights. During both nights, a significant elevation of melatonin levels in medetomidine-injected rats was found 2 h later than in control rats. We interpret the first-night delay to be a sign of medetomidine's suppressive effect on melatonin synthesis, and the second-night delay a medetomidine-induced resetting of the circadian clock controlling the melatonin onset.